Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macroleave: Discontinuation of long-term azithromycin in stable non-cystic fibrosis bronchiectasis
2025-521493-33-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Intercommunal de Créteil
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of azithromycin in bronchiectasis (2 arms), sponsored by Centre Hospitalier Intercommunal de Créteil. Primary endpoint: Annualized number of pulmonary exacerbations. Planned start Jul 2026; status: authorised.
02
Drugs
azithromycin
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2025-521493-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521493-33-00.